IN

Inozyme Pharma IncNASDAQ INZY Stock Report

Last reporting period 30 Sep, 2023

Updated 18 Nov, 2024

Last price

Market cap $B

0.328

Micro

Exchange

XNAS - Nasdaq

INZY Stock Analysis

IN

Uncovered

Inozyme Pharma Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.328

Dividend yield

Shares outstanding

40.394 B

Inozyme Pharma engages in the research and development of novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. The company is headquartered in Boston, Massachusetts and currently employs 50 full-time employees. The company went IPO on 2020-07-24. The firm is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The firm's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Its INZ-701 is in Phase I/II clinical trials for the treatment of ENPP1 deficiency and ABCC6 deficiency.

View Section: Eyestock Rating